Close Menu

head and neck cancer

Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.

In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors. 

The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.

In Science this week: rare NOTCH signaling pathway mutations drive many head and neck squamous cell carcinomas, and more.

Genes influencing NOTCH pathway activity were linked to head and neck squamous cell carcinoma with a mouse screen centered on genes with long tail mutations in human cases.

The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.

The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.

Researchers at MD Anderson Cancer Center found that somatic copy number alterations are more frequent in normal tissue surrounding tumor than in blood.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.